Chromatin structure analyses identify miRNA promoters
Ozsolak, Fatih, Poling, Laura L, Wang, Zhengxin, Liu, Hui, Liu, X Shirley, Roeder, Robert G, Zhang, Xinmin, Song, Jun S, Fisher, David E
Published in Genes & development (15.11.2008)
Published in Genes & development (15.11.2008)
Get full text
Journal Article
Dolaflexin: A Novel Antibody-Drug Conjugate Platform Featuring High Drug Loading and a Controlled Bystander Effect
Yurkovetskiy, Aleksandr V, Bodyak, Natalya D, Yin, Mao, Thomas, Joshua D, Clardy, Susan M, Conlon, Patrick R, Stevenson, Cheri A, Uttard, Alex, Qin, LiuLiang, Gumerov, Dmitry R, Ter-Ovanesyan, Elena, Bu, Charlie, Johnson, Alex J, Gurijala, Venu R, McGillicuddy, Dennis, DeVit, Michael J, Poling, Laura L, Protopopova, Marina, Xu, Ling, Zhang, Qingxiu, Park, Peter U, Bergstrom, Donald A, Lowinger, Timothy B
Published in Molecular cancer therapeutics (01.05.2021)
Published in Molecular cancer therapeutics (01.05.2021)
Get full text
Journal Article
The Dolaflexin-based Antibody-Drug Conjugate XMT-1536 Targets the Solid Tumor Lineage Antigen SLC34A2/NaPi2b
Bodyak, Natalya D, Mosher, Rebecca, Yurkovetskiy, Aleksandr V, Yin, Mao, Bu, Charlie, Conlon, Patrick R, Demady, Damon R, DeVit, Michael J, Gumerov, Dmitry R, Gurijala, Venu R, Lee, Winnie, McGillicuddy, Dennis, Park, Peter U, Poling, Laura L, Protopova, Marina, Qin, LiuLiang, Stevenson, Cheri A, Ter-Ovanesyan, Elena, Uttard, Alex, Xiao, Dongmei, Xu, Jian, Xu, Ling, Bergstrom, Donald A, Lowinger, Timothy B
Published in Molecular cancer therapeutics (01.05.2021)
Published in Molecular cancer therapeutics (01.05.2021)
Get full text
Journal Article
GP369, an FGFR2-IIIb-Specific Antibody, Exhibits Potent Antitumor Activity against Human Cancers Driven by Activated FGFR2 Signaling
AILIN BAI, MEETZE, Kristan, JINWEI JIANG, LERNER, Lorena, GYURIS, Jeno, ZHIGANG WENG, VO, Nhi Y, KOLLIPARA, Sriram, MAZSA, Elizabeth K, WINSTON, William M, WEILER, Solly, POLING, Laura L, TING CHEN, ISMAIL, Nesreen S
Published in Cancer research (Chicago, Ill.) (01.10.2010)
Published in Cancer research (Chicago, Ill.) (01.10.2010)
Get full text
Journal Article
The colonization of land by animals: molecular phylogeny and divergence times among arthropods
Pisani, Davide, Poling, Laura L, Lyons-Weiler, Maureen, Hedges, S Blair
Published in BMC biology (19.01.2004)
Published in BMC biology (19.01.2004)
Get full text
Journal Article
Pharmacologic suppression of MITF expression via HDAC inhibitors in the melanocyte lineage
Yokoyama, Satoru, Feige, Erez, Poling, Laura L., Levy, Carmit, Widlund, Hans R., Khaled, Mehdi, Kung, Andrew L., Fisher, David E.
Published in Pigment cell and melanoma research (01.08.2008)
Published in Pigment cell and melanoma research (01.08.2008)
Get full text
Journal Article
Abstract 596: Optimization of lead antibody selection for XMT-1522, a novel, highly potent HER2-targeted antibody-drug conjugate (ADC)
Bodyak, Natasha, Yurkovetskiy, Alex, Gumerov, Dmitry R., Xiao, Dongmei, Thomas, Joshua D. Thomas D., Poling, Laura L., Qin, LiuLiang, Yin, Mao, DeVit, Michael J., Park, Peter U., Lee, Winnie, Prinz, Bianka, Bergstrom, Donald A., Lowinger, Timothy B.
Published in Cancer research (Chicago, Ill.) (15.07.2016)
Published in Cancer research (Chicago, Ill.) (15.07.2016)
Get full text
Journal Article
A Molecular Phylogeny of Reptiles
Hedges, S. Blair, Poling, Laura L.
Published in Science (American Association for the Advancement of Science) (12.02.1999)
Published in Science (American Association for the Advancement of Science) (12.02.1999)
Get full text
Journal Article
CFT8634, a Clinical Stage BRD9 Bi DAC™ Degrader, Is Active in a Subset of Multiple Myeloma Cell Line Models and Synergistic When Combined with Pomalidomide
Poling, Laura L, Cocozziello, David, He, Minsheng, Hurh, Eunju, Lobbardi, Riadh, Jackson, Katrina L, Fisher, Stewart L, Pollock, Roy M
Published in Blood (02.11.2023)
Published in Blood (02.11.2023)
Get full text
Journal Article
Abstract B119: Relationship of NaPi2b expression and efficacy of XMT-1536, a NaPi2b targeting antibody-drug conjugate (ADC), in an unselected panel of human primary ovarian mouse xenograft models
Mosher, Rebecca, Poling, Laura, Qin, LiuLiang, Bodyak, Natalya, Bergstrom, Donald
Published in Molecular cancer therapeutics (01.01.2018)
Published in Molecular cancer therapeutics (01.01.2018)
Get full text
Journal Article
Abstract 6046: CFT8634, a BRD9 BiDAC™ degrader, is active in a subset of multiple myeloma cell line models and synergistic when combined with pomalidomide or dexamethasone
Poling, Laura L., Cocozziello, David, he, Minsng, Hurh, Eunju, Lobbardi, Riadh, Jackson, Katrina L., Fisher, Stewart L., Pollock, Roy M.
Published in Cancer research (Chicago, Ill.) (22.03.2024)
Published in Cancer research (Chicago, Ill.) (22.03.2024)
Get full text
Journal Article
Abstract 1658: CFT1946, a potent, selective BRAF V600X mutant-specific degrader demonstrates superior activity as a single agent to clinically approved BRAF inhibitors and standard of care combinations in preclinical models of BRAF V600X melanoma, CRC, NSCLC, and brain metastasis
Kreger, Bridget, Stephenson, Jacob R., Sowa, Mathew E., Perino, Samantha A., Poling, Laura L., Hurh, Eunju, Thomenius, Michael J., Liang, Yanke, Fisher, Stewart L., Pollock, Roy M.
Published in Cancer research (Chicago, Ill.) (22.03.2024)
Published in Cancer research (Chicago, Ill.) (22.03.2024)
Get full text
Journal Article
Abstract 2670: Combination of anti-HER2 ADC XMT-1522 and checkpoint inhibitor pembrolizumab for treatment of NSCLC in preclinical models
Bodyak, Natalya, Protopopova, Marina, Zhang, Qingxiu, Yurkovetskiy, Alex, Yin, Mao, Qin, LiuLiang, Poling, Laura L., Mosher, Rebecca, Bergstrom, Donald A., Lowinger, Timothy B.
Published in Cancer research (Chicago, Ill.) (01.07.2017)
Published in Cancer research (Chicago, Ill.) (01.07.2017)
Get full text
Journal Article
MA09.10 A NaPi2b Antibody-Drug Conjugate Induces Durable Complete Tumor Regressions in Patient-Derived Xenograft Models of NSCLC
Bergstrom, Donald, Bodyak, Natalya, Yurkovetskiy, Alex, Poling, Laura, Yin, Mao, Protopopova, Marina, Devit, Mike, Qin, Liuliang, Gumerov, Dmitry, Ter-Ovanesyan, Elena, Mosher, Rebecca, Lowinger, Timothy
Published in Journal of thoracic oncology (01.01.2017)
Published in Journal of thoracic oncology (01.01.2017)
Get full text
Journal Article
Abstract 1194: Discovery and preclinical development of a highly potent NaPi2b-targeted antibody-drug conjugate (ADC) with significant activity in patient-derived non-small cell lung cancer (NSCLC) xenograft models
Bodyak, Natalya, Yurkovetskiy, Alex, Yin, Mao, Gumerov, Dmitry, Bollu, Reddy, Conlon, Patrick, Gurijala, Venu R., McGillicuddy, Dennis, Stevenson, Cheri, Ter-Ovanesyan, Elena, Park, Peter U., Poling, Laura, Lee, Winnie, DeVit, Michael, Xiao, Dongmei, Qin, LiuLiang, Lowinger, Timothy B., Bergstrom, Donald A.
Published in Cancer research (Chicago, Ill.) (15.07.2016)
Published in Cancer research (Chicago, Ill.) (15.07.2016)
Get full text
Journal Article
23814, an Inhibitory Antibody of Ligand-Mediated Notch1 Activation, Modulates Angiogenesis and Inhibits Tumor Growth without Gastrointestinal Toxicity
Proia, Theresa, Jiang, Feng, Bell, Alisa, Nicoletti, Richard, Kong, Lingxin, Kreuter, Kelly, Poling, Laura, Winston, William M, Flaherty, Meghan, Weiler, Solly, Perino, Samantha, O'Hagan, Ronan, Lin, Jie, Gyuris, Jeno, Okamura, Heidi
Published in Molecular cancer therapeutics (01.08.2015)
Published in Molecular cancer therapeutics (01.08.2015)
Get full text
Journal Article
Abstract ND05: The discovery and characterization of CFT1946: A potent, selective, and orally bioavailable degrader of mutant BRAF for the treatment of BRAF-driven cancers
Liang, Yanke, Sowa, Mathew E., Jackson, Katrina L., Simard, Jeffrey R., Kreger, Bridget, Li, Ping, Poling, Laura, Baddour, Joelle, Good, Andrew, Huang, Hongwei, Eron, Scott, Nasveschuk, Christopher G., Yu, Robert, Fitzgerald, Mark, Garza, Victoria, O’Shea, Morgan W., Veits, Gesine, Yap, Jeremy L., Moustakim, Moses, Hart, Ashley, Agafonov, Roman V., Sarkissian, Grace, Patel, Joe S., Deibler, Richard, Cole, Kyle S., Cocozziello, David, Rahman, Fazlur, Phillips, Andrew J., Norton, Elizabeth, Crystal, Adam S., Pollock, Roy M., Fisher, Stewart L.
Published in Cancer research (Chicago, Ill.) (29.05.2023)
Published in Cancer research (Chicago, Ill.) (29.05.2023)
Get full text
Journal Article
Abstract 3425: The discovery and characterization of CFT1946: A potent, selective, and orally bioavailable degrader of mutant BRAF for the treatment of BRAF-driven cancers
Liang, Yanke, Sowa, Mathew E., Jackson, Katrina L., Simard, Jeffrey R., Kreger, Bridget, Li, Ping, Poling, Laura, Baddour, Joelle, Good, Andrew, Huang, Hongwei, Eron, Scott, Nasveschuk, Christopher G., Yu, Robert, Fitzgerald, Mark, Garza, Victoria, O’Shea, Morgan W., Veits, Gesine, Yap, Jeremy Y., Moustakim, Moses, Hart, Ashley, Agafonov, Roman V., Sarkissian, Grace, Patel, Joe S., Deibler, Richard, Cole, Kyle S., Cocozziello, David, Rahman, Fazlur, Phillips, Andrew J., Norton, Elizabeth, Crystal, Adam S., Pollock, Roy M., Fisher, Stewart L.
Published in Cancer research (Chicago, Ill.) (04.04.2023)
Published in Cancer research (Chicago, Ill.) (04.04.2023)
Get full text
Journal Article
Abstract 2158: Preclinical evaluation of CFT1946 as a selective degrader of mutant BRAF for the treatment of BRAF driven cancers
Sowa, Mathew E., Kreger, Bridget, Baddour, Joelle, Liang, Yanke, Simard, Jeffrey R., Poling, Laura, Li, Ping, Yu, Robert, Hart, Ashley, Agafonov, Roman V., Sarkissian, Grace, Patel, Joe Sahil, Deibler, Richard, Cole, Kyle S., Eron, Scott, Cocozziello, David, Rahman, Fazlur, Moustakim, Moses, Nasveschuk, Christopher G., Jackson, Katrina L., Fitzgerald, Mark, Garza, Victoria, O’Shea, Morgan, Veits, Gesine, Yap, Jeremy L., Phillips, Andrew J., Norton, Elizabeth, Crystal, Adam S., Fisher, Stewart L., Pollock, Roy M.
Published in Cancer research (Chicago, Ill.) (15.06.2022)
Published in Cancer research (Chicago, Ill.) (15.06.2022)
Get full text
Journal Article